Pharmaceuticals
November 24, 2021
Robertas Strumila, Bénédicte Nobile, Laura Korsakova et al.
35 citations
Current interventions for people at risk of suicide have limited efficacy. This review examines whether psilocybin, a psychedelic compound with a long history of human use, could modulate thoughts and behavioral patterns in individuals at risk of suicidal behaviors. The authors summarize evidence that psilocybin directly stimulates the serotonin 2A receptor (5HT2A), targeting inflammatory and oxidative stress pathways, which may lead to rapid increases in brain plasticity, cognitive flexibility, spirituality, and empathy, while suppressing inflammation. Preliminary epidemiological data are presented, and the review calls for clinical studies to test psilocybin in individuals with suicidal ideation or at risk of suicidal behaviors.
European psychiatry : the journal of the Association of European Psychiatrists
August 26, 2025
Ismael Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al.
2 citations
In a naturalistic study across four Madrid hospitals, 55% of 65 patients with treatment-resistant depression who received esketamine as an augmentation treatment achieved remission over follow-up. Among those who completed the standard protocol, remission rates rose to 67%, and to 70% for those receiving more than 19 administrations. Remission was associated with completing the standard protocol and with the absence of dissociative symptoms. Receiving more than 19 esketamine administrations increased the odds of remission. Adverse effects did not affect treatment continuation.
International journal of environmental research and public health
March 27, 2025
Déborah Ducasse, Martin Leurent, Marie-Christine Picot et al.
1 citation
A French version of the Ontological Addiction Scale (OAS) was validated in 492 French adults with emotional or mood disorders. The scale measures ontological addiction, a dysfunctional self-concept where individuals see themselves as separate from their surroundings. The French OAS showed good internal consistency (Cronbach's alpha: 0.89) and strong test-retest reliability, with a single-factor structure matching the original English version. A 12-item version also had good internal consistency (Cronbach's alpha: 0.81). Construct validity was supported by medium to large correlations with self-esteem, shame, perfectionism, and mindfulness. The French OAS is a robust tool for assessing ontological addiction in research and clinical practice.
Clinics and practice
June 12, 2026
Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.
In a six-month naturalistic study of 62 patients with treatment-resistant depression and high suicide risk, those receiving intranasal esketamine showed faster and greater reductions in suicidal thoughts and depressive symptoms compared to those receiving alternative pharmacological treatments. The number needed to treat to prevent one case of high suicide risk was 1.35. Functional improvement was similar between groups. The findings support esketamine as a rapid-acting option in real-world, closely monitored care.
Medecine sciences : M/S
May 1, 2025
Aiste Lengvenyte, Émilie Olié, Marion Leboyer et al.
Suicidal thoughts and behaviors form a distinct dimension that cuts across psychiatric diagnoses, supported by genetic, biomarker, and preclinical evidence. Key endophenotypes include impulsivity, anhedonia, and hopelessness, with emerging mechanisms in inflammation, stress response, serotonin function, and neuroplasticity. Treatments like lithium and ketamine target these pathways. The French Minds cohort within the PEPR PROPSY project will use multimodal approaches to identify biological signatures and trajectories of this dimension.